ALFA Finder| Management target | Revenue FY30 |
|---|
| Revenue growth | 23% YoY decline driven by shipment phasing and CDMO destocking. |
|---|---|
| Margins | EBITDA margins severely compressed to 2.2% due to low revenue base. |
| Order book | Significant commercial restocking orders secured for Q4 FY27 and FY28. |
| Demand visibility | Strong RFQ pipeline in late-stage molecules and ADC payloads. |
| Management confidence | Balanced; acknowledging Q1 as a historic low while projecting H2 recovery. |
Growth
Pharma CDMO revenue plunged 38.7% YoY due to destocking, partially offset by 2.5x growth in the Sapala subsidiary.
Outlook
Management expects sequential improvement in Q2 and a return to YoY growth starting in H2 FY27.
Risks
Heavy negative operating leverage at Enzene Biosciences and persistent biotech funding headwinds impact near-term profitability.
Last quarter's promises, checked
Delivered
- Guided Q4/FY26 in line with guidance → delivered FY26 revenue 22.68B (= BEAT)
- Guided FY26 Gross Margin supported by mix → delivered 70.8% (= BEAT)
- Guided FY26 Capex at 2.15B → delivered 2.15B (= BEAT)
Partly delivered
- Guided 10 Phase 3 programs → delivered 10 programs but with biotech delays (= PARTIAL)
Missed
- Guided H2 FY27 growth → delivered Q1 FY27 23% revenue decline (= MISS)
- Guided API+ stability → delivered Q1 FY27 shipment phasing/delays (= MISS)
- Guided EBITDA margin benchmark 30% → delivered 2.2% in Q1 FY27 (= MISS)
Earnings Call Transcript filed with NSE, NSE: COHANCE. Summary written with AI assistance from the document.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹460.10
- Market cap
- ₹17,604 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 371.6×Sector 43.8×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Capital Structure Change
Jasti group entities transferred 51,00,000 Cohance shares to Jasub Property Holdings LLP via inter-se block deals. Combined group holding remains 6.36%.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Investor Presentation: Key Takeaways
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.